Based on the findings of our research, we propose that NF-κB may present a new target for anti-inflammatory therapies in myocarditis with elevated FLCs and, further, that FLCs may serve as an alternate endpoint for the treatment of myocarditis. Here, NFKB1 is linked to myocarditis.